Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04428775 · ClinicalTrials.gov registry record · Phase 2
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
A Phase 2 study, sponsored by AZTherapies.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04428775 is a Phase 2 study that was terminated before completion, run by AZTherapies. The registered enrollment target is 12 participants.
The verdict
NCT04428775, a Phase 2 study, was terminated before completion, sponsored by AZTherapies.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.
Interventions
- DRUG ALZT-OP1a (cromolyn)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04428775
The ClinicalTrials.gov registry entry for NCT04428775 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AZTherapies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALZT-OP1a (cromolyn) is the first listed.
NCT04428775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04428775 about?
NCT04428775 is a clinical study titled "A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease". This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild ...
What is the current status of trial NCT04428775?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-09-08. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04428775?
The interventions under investigation include: ALZT-OP1a (cromolyn) (DRUG).
Who is sponsoring clinical trial NCT04428775?
This trial is sponsored by AZTherapies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.